外陰がん市場- 世界の産業規模、シェア、動向、機会、予測、がんの種類別、治療の種類別、エンドユーザー別、地域別、競合別、2020～2030年

外陰がんの世界市場は、2024年に6億1,204万米ドルと評価され、予測期間には8億8,580万米ドルに達すると予測され、2030年までのCAGRは6.33%です。

外陰がんの世界市場は、治療オプションの顕著な進歩、認知度の向上、疾患に対する理解の深まりとともに発展しています。外陰がんは希少ながんの一種で、主に高齢の女性が罹患し、世界の高齢化の進展に伴い罹患率の増加が見込まれています。市場の成長には、免疫療法、生物学的製剤、低侵襲手術など、より効果的で的を絞った治療オプションのイントロダクションが寄与しています。これにより、外陰がんと診断された患者の予後が改善し、生存率が高まり、生活の質が向上しています。さらに、外陰がんとその症状に対する認知度の高まりにより、早期発見が促進され、治療成績の向上に寄与すると期待されています。

免疫チェックポイント阻害薬や個別化医療などの革新的な治療に対する需要が、今後数年間の市場を牽引すると予想されます。最近の免疫療法の動向はがん治療に革命をもたらしており、こうした進歩は外陰がんの患者にとって有望なものとなりつつあります。さらに、臨床試験と研究資金への注目の高まりが新薬と治療レジメンの開発を後押しし、より効果的で的を絞った治療への希望をもたらしています。個別化治療の選択肢の増加と、腫瘍学における精密医療へのシフトが、市場の拡大をさらに後押ししています。

こうした前向きな動きにもかかわらず、世界の外陰がん市場にはいくつかの課題が残っています。特に低・中所得国での認知度の低さは依然として大きなハードルであり、多くの女性がこの病気に関する教育不足のために診断や治療を遅らせている可能性があります。また、先進治療、特に生物学的製剤や免疫療法薬に伴う高額な治療費も、すべての患者がこれらの治療を受けられるわけではないため、市場成長の障壁となっています。さらに、外陰がんに必要な手術、放射線、化学療法などの複雑かつ集学的な治療アプローチは、患者にとって治療の旅を困難なものにしています。しかし、現在進行中の調査、パートナーシップ、医療投資の増加は、こうした課題を克服し、市場の継続的成長を促進する機会を提供しています。

主な市場促進要因

外陰がんの発生率の上昇

主な市場課題

認知度の低下と早期発見

主要市場動向

標的療法と免疫療法の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の外陰がん市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • がんの種類別（外陰部扁平上皮がん、外陰部黒色腫、腺がん、基底細胞がん）
  • 治療の種類別（化学療法、手術、レーザー手術、切除、皮膚切除術、根治的外陰切除術、放射線外陰切除術、生物学的療法）
  • エンドユーザー別（病院・診療所、調査・学術機関、その他）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米の外陰がん市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の外陰がん市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の外陰がん市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の外陰がん市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの外陰がん市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収（ある場合）
• 製品の発売（ある場合）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Merck & Co. Inc.
• Sanofi SA
• Novartis AG
• Astellas Pharma Inc.
• Pfizer Inc.
• Abbott Laboratories
• Bristol-Myers Squibb Company
• Takeda Pharmaceutical Company Limited
• F. Hoffmann-La Roche Ltd
• Eli Lilly and Company

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Vulvar Cancer Market was valued at USD 612.04 Million in 2024 and is expected to reach USD 885.80 Million in the forecast period with a CAGR of 6.33% through 2030. The Global Vulvar Cancer Market is evolving with notable advancements in treatment options, increasing awareness, and a growing understanding of the disease. Vulvar cancer, a rare form of cancer, primarily affects older women, and its incidence is expected to rise as the aging population increases globally. The market growth is fueled by the introduction of more effective and targeted treatment options, such as immunotherapies, biologic therapies, and minimally invasive surgeries. This has allowed for better patient outcomes, higher survival rates, and improved quality of life for those diagnosed with vulvar cancer. Furthermore, the rising awareness of vulvar cancer and its symptoms is expected to enhance early detection, contributing to better treatment outcomes.

The demand for innovative therapies, such as immune checkpoint inhibitors and personalized medicine, is expected to drive the market in the coming years. Recent developments in immunotherapy have revolutionized cancer treatment, and these advancements are beginning to show promise for vulvar cancer patients. Additionally, the increased focus on clinical trials and research funding has bolstered the development of new drugs and treatment regimens, offering hope for more effective and targeted therapies. The growth of personalized treatment options and the shift towards precision medicine in oncology further support the expanding market, as patients are increasingly being treated based on their unique genetic profiles, which improves treatment success rates.

Despite the positive developments, several challenges persist within the Global Vulvar Cancer Market. Limited awareness, especially in low- and middle-income countries, remains a significant hurdle, as many women may delay diagnosis and treatment due to a lack of education on the disease. High treatment costs associated with advanced therapies, especially biologic and immunotherapy drugs, also pose barriers to market growth, as not all patients have access to these therapies. Moreover, the complex and multidisciplinary treatment approach required for vulvar cancer, including surgery, radiation, and chemotherapy, makes the treatment journey difficult for patients. However, ongoing research, partnerships, and increasing healthcare investment offer opportunities for overcoming these challenges and driving continued market growth.

Key Market Drivers

Rising Incidence of Vulvar Cancer

The increasing incidence of vulvar cancer significantly propels the growth of the global vulvar cancer market. Vulvar cancer, though relatively rare, has shown a concerning rise in cases. According to data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program, the rate of new vulvar cancer cases was 2.6 per 100,000 women annually between 2017 and 2021, with an estimated 6,900 new diagnoses in 2024 alone.

A significant contributor to this rise is the prevalence of human papillomavirus (HPV) infections. The Centers for Disease Control and Prevention (CDC) reports that approximately 69% of vulvar cancer cases are attributable to HPV. Despite the availability of HPV vaccines, vaccination coverage remains suboptimal. In 2022, only 38.6% of children aged 9-17 years had received at least one dose of the HPV vaccine, potentially leading to a higher risk of HPV-related cancers in the future.

Age is another critical factor, as vulvar cancer is most frequently diagnosed among women aged 65 to 74, with a median age at diagnosis of 69 years. The global increase in life expectancy and the growing elderly population contribute to the rising number of cases. Additionally, chronic inflammatory conditions like lichen sclerosus have been linked to an increased risk of developing vulvar cancer.

Enhanced awareness and improved diagnostic capabilities have also led to higher reported cases. Advancements in medical imaging and pathology enable earlier and more accurate detection, facilitating timely intervention. However, lifestyle factors such as tobacco use and obesity further exacerbate the risk, as these have been associated with a higher likelihood of developing various cancers, including those of the vulva.

The combination of these factors has led to increased demand for comprehensive diagnostic tools, effective treatment modalities, and supportive care services, thereby significantly influencing the expansion of the vulvar cancer treatment market.

Key Market Challenges

Limited Awareness and Early Detection

One of the primary challenges confronting the Global Vulvar Cancer Market is the limited awareness of this specific form of cancer among the general public. Unlike more prevalent cancers, such as breast or lung cancer, vulvar cancer often remains in the shadows. This lack of awareness results in delayed diagnosis, as symptoms are not recognized promptly. Many women may ignore warning signs or attribute them to less serious conditions, causing a delay in seeking medical attention.

Sociocultural taboos and stigmas surrounding reproductive and genital health can exacerbate the problem. Open discussions about vulvar cancer symptoms and prevention are often discouraged or considered taboo in many societies. This silence further contributes to the lack of awareness and inhibits early detection efforts. Early detection of vulvar cancer is crucial for successful treatment and improved outcomes. Delayed diagnosis can lead to more advanced stages of the disease, necessitating more aggressive and costly treatments. Addressing the challenge of limited awareness and early detection requires educational campaigns, public health initiatives, and healthcare providers actively promoting regular check-ups and screening for at-risk populations.

Key Market Trends

Advances in Targeted Therapies and Immunotherapy

Advances in targeted therapies and immunotherapy are significantly influencing the Global Plasma Expander Market. These therapies, which focus on specific molecules involved in disease progression, have revolutionized the treatment of various conditions, particularly cancer and autoimmune diseases. As the adoption of immunotherapy and targeted therapies increases, so does the need for effective management of their associated side effects, such as fluid imbalances and hypovolemia. Plasma expanders play a crucial role in stabilizing patients undergoing aggressive cancer treatments or organ transplants, where rapid blood volume restoration is essential for maintaining hemodynamic stability.

In India, the incidence of cancer has been rising steadily. According to the National Cancer Registry Programme, the age-adjusted incidence rate of cancer in India is approximately 97.8 per 100,000 population. This increase in cancer cases correlates with a higher number of patients undergoing chemotherapy and immunotherapy, both of which can lead to complications like anemia, weakness, and fluid imbalances. For instance, a study published in the Annual Report 2021-2022 by Tata Memorial Hospital reported that the most common side effects resulting from metronomic chemotherapy were anemia (63.5%) and weakness (57.7%).

The Department of Biotechnology in India has been actively supporting research in stem cell therapies and immunotherapies, which are increasingly being integrated into cancer treatment protocols. These advanced therapies often necessitate the use of plasma expanders to manage side effects effectively. The Department's Annual Report 2020-21 highlights ongoing support for basic, early, and late translational research in the area of stem cells and immunotherapies.

As the healthcare landscape evolves with the integration of targeted therapies and immunotherapies, the demand for plasma expanders is expected to rise. These products are essential in managing the complex side effects associated with advanced treatments, thereby improving patient outcomes and contributing to the growth of the global market.

Key Market Players

• Merck & Co. Inc.
• Sanofi SA
• Novartis AG
• Astellas Pharma Inc.
• Pfizer Inc.
• Abbott Laboratories
• Bristol-Myers Squibb Company
• Takeda Pharmaceutical Company Limited
• F. Hoffmann-La Roche Ltd
• Eli Lilly and Company

Report Scope:

In this report, the Global Vulvar Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Vulvar Cancer Market, By Cancer Type:

• Vulvar Squamous Cell Carcinoma
• Vulvar Melanoma
• Adenocarcinoma
• Basal Cell Carcinoma

Vulvar Cancer Market, By Treatment Type:

• Chemotherapy, Surgery
• Laser Surgery
• Excision
• Skinning Vulvectomy
• Radical Vulvectomy
• Radiation Vulvectomy
• Biologic Therapy

Vulvar Cancer Market, By End-User:

• Hospitals & Clinics
• Research & Academic Institutes
• Others

Vulvar Cancer Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Vulvar Cancer Market.

Available Customizations:

Global Vulvar Cancer market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Vulvar Cancer Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Cancer Type (Vulvar Squamous Cell Carcinoma, Vulvar Melanoma, Adenocarcinoma, Basal Cell Carcinoma)
  • 5.2.2. By Treatment Type (Chemotherapy, Surgery, Laser Surgery, Excision, Skinning Vulvectomy, Radical Vulvectomy, Radiation Vulvectomy, Biologic Therapy)
  • 5.2.3. By End-User (Hospitals & Clinics, Research & Academic Institutes, Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Vulvar Cancer Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Cancer Type
  • 6.2.2. By Treatment Type
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Vulvar Cancer Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Cancer Type
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By End-User
  • 6.3.2. Mexico Vulvar Cancer Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Cancer Type
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By End-User
  • 6.3.3. Canada Vulvar Cancer Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Cancer Type
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By End-User

7. Europe Vulvar Cancer Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Cancer Type
  • 7.2.2. By Treatment Type
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Vulvar Cancer Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Cancer Type
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By End-User
  • 7.3.2. Germany Vulvar Cancer Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Cancer Type
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By End-User
  • 7.3.3. United Kingdom Vulvar Cancer Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Cancer Type
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By End-User
  • 7.3.4. Italy Vulvar Cancer Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Cancer Type
      • 7.3.4.2.2. By Treatment Type
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Vulvar Cancer Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Cancer Type
      • 7.3.5.2.2. By Treatment Type
      • 7.3.5.2.3. By End-User

8. Asia-Pacific Vulvar Cancer Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Cancer Type
  • 8.2.2. By Treatment Type
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Vulvar Cancer Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Cancer Type
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By End-User
  • 8.3.2. India Vulvar Cancer Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Cancer Type
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By End-User
  • 8.3.3. South Korea Vulvar Cancer Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Cancer Type
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By End-User
  • 8.3.4. Japan Vulvar Cancer Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Cancer Type
      • 8.3.4.2.2. By Treatment Type
      • 8.3.4.2.3. By End-User
  • 8.3.5. Australia Vulvar Cancer Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Cancer Type
      • 8.3.5.2.2. By Treatment Type
      • 8.3.5.2.3. By End-User

9. South America Vulvar Cancer Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Cancer Type
  • 9.2.2. By Treatment Type
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Vulvar Cancer Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Cancer Type
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By End-User
  • 9.3.2. Argentina Vulvar Cancer Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Cancer Type
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By End-User
  • 9.3.3. Colombia Vulvar Cancer Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Cancer Type
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By End-User

10. Middle East and Africa Vulvar Cancer Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Cancer Type
  • 10.2.2. By Treatment Type
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Vulvar Cancer Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Cancer Type
      • 10.3.1.2.2. By Treatment Type
      • 10.3.1.2.3. By End-User
  • 10.3.2. Saudi Arabia Vulvar Cancer Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Cancer Type
      • 10.3.2.2.2. By Treatment Type
      • 10.3.2.2.3. By End-User
  • 10.3.3. UAE Vulvar Cancer Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Cancer Type
      • 10.3.3.2.2. By Treatment Type
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Merck & Co. Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Sanofi SA
• 14.3. Novartis AG
• 14.4. Astellas Pharma Inc.
• 14.5. Pfizer Inc.
• 14.6. Abbott Laboratories
• 14.7. Bristol-Myers Squibb Company
• 14.8. Takeda Pharmaceutical Company Limited
• 14.9. F. Hoffmann-La Roche Ltd
• 14.10. Eli Lilly and Company

15. Strategic Recommendations

16. About Us & Disclaimer